Regen BioPharma, Inc. invites individual and institutional investors as well as advisors and analysts to attend its real-time interactive presentation at the Emerging Growth Conference.
SAN DIEGO, November 28, 2022 /PRNewswire/ — Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) (a biotechnology company advancing a diverse preclinical pipeline spanning cell therapies, RNA vaccines, RNA and DNA and Small Molecule Drugs) will present at the Emerging Growth Conference on November 30, 2022 (https://emerginggrowth.com/conference/).
This live online event will provide existing shareholders and the investment community with the opportunity to interact with the company’s CEO, Dr. David Koos in real time. Please ask your questions during the event and Dr. Koos and his team will do their best to address as many as possible.
“We plan to use this time to update our shareholders on our CAR T cell development program,” says Dr. David KoosCEO and President of the Company.
Regen BioPharma, Inc. will present 1:45 – 2:00 Eastern Time WednesdayNovember 30, 2022. Please register here to ensure you can attend the conference and receive all posted updates https://goto.webcasts.com/starthere.jsp?ei=1575088&tp_key=b1fead5049&sti=rgbp.
If attendees are unable to join the live event on the day of the conference, an archived webcast will also be available on EmergingGrowth.com.
About the Emerging Growth Conference
The Emerging Growth Conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the comfort of their office, efficiently.
The focus and coverage of the conference includes companies in a wide range of growth industries, with strong management teams, innovative products and services, focused strategy, execution and overall long-term growth potential. Its audience potentially includes tens of thousands of individual and institutional investors, as well as investment advisers and analysts.
About Regen BioPharma Inc.:
Regen BioPharma, Inc. is a publicly traded biotechnology company (PINK: RGBP) and (PINK: RGBPP). The Company is focused on the field of immunology and immunotherapy. The company is focused on rapidly advancing new technologies through preclinical and Phase I/II clinical trials. Currently, the Company is focused on mRNA and small molecule therapies for the treatment of cancer and autoimmune diseases. Additional information about Regen BioPharma is available at http://www.regenbiopharmainc.com.
Disclaimer: This announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those stated, contemplated or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Regen BioPharma Inc.
David R. Koosdoctorate
Follow us on Twitter for future updates: https://twitter.com/TheRegenBio
SOURCERegen BioPharma, Inc.